2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 313 | - | - | ||
| 65 | - | - | ||
| 29 | - | - | ||
| 1 037 | - | - | ||
| 57 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 721 971 | 721 971 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 721 971 | 721 971 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 t sitten · MuokattuIf one wants to do some research oneself, here is an interesting document. Together with ChatGPT, I have uploaded Redeye's overview in an Excel sheet and this document, and asked what ChatGPT thinks about it. One can easily buy into 4-5 Phase I projects already now if one wants and put in an F1->F2 LoA now and say it's a fair price - personally I just won't pay for Phase 1 until we are there!l A bit of the ChatGPT dialogue comes here, if one finds it fun - it's a bit of an attempt to take emotions out, so one can always add a bit related to it afterwards: When the individual projects then enter clinical phase - and further to the next phase, one can adjust LoA - the same can be done if new projects, new agreements, new money come in, or if a project is closed. Unfortunately, I cannot upload an Excel sheet, but I think one can quickly make it oneself from Redeye's analysis - that's what I have done myself. ----------------------------------------- Question to ChatGPT: If you were to put some LoA into the attached Excel sheet, what would you put in column M - and would you add something to the calculation. What do you think about the calculation in column O Thought for 6m 19s Yes. I would set column M like this in a 1-factor model: SAN711 Epilepsy: 10% SAN711 Essential Tremor: 18% Tesomet HO/PwS: 25% Tesofensine Obesity: 85% AstronauTx Alzheimer: 2% SAN2355 Epilepsy: 4% SAN2465 Major Depression: 2% Boehringer Schizophrenia: 2% SAN2668 ESES/DEEs: 5% SAN2219 Epilepsy: 3% SAN903: 5% CAD1883: 10% (only if you want to keep the row active) The background is especially that SAN2219 and SAN2465 are still preclinical, SAN2668 first moves towards Phase I in 2026, Tesomet is paused due to funding, Tesofensine is regulatory/NDA-submitted in Mexico, and SAN903 is “ready for clinical studies”. ACP-711/SAN711 has completed Phase I and aims for Phase II in essential tremor. BIO 2011–2020 also supports lower probabilities for CNS than for the average, while rare disease is higher. The most important thing, however, is: I would add an extra factor to the calculation — not mix everything into LoA alone. Add, for example, an auxiliary column with: Execution / funding / partner factor This is especially relevant for: Tesomet (paused) SAN711 epilepsy (more optionality than lead program) discovery/collab-assets like AstronauTx/BI Then the model becomes: Risked value = Unrisked NPV × Technical LoA × Execution factor https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf?utm_source=chatgpt.com
·1 päivä sittenShorts are wrong! This is a top-tier company -now on sale.·22 t sitten · MuokattuNice to hear from the man who sits with the crayons, draws some lines in a chart and changes LOA in an analysis until the puzzle fits his own agenda. Of course the price is 'exactly where it should be' then ;)·9 t sitten · MuokattuJUSTICE: That's essentially also what Redeye’s and AktieInfo’s analysts do - so maybe you'd like to share your target price calculations - then one can compare!? They conduct analyses of the products, research, and the market - then they have some assumptions they apply to everything, which they then convert into numbers and a target price - not just sharing “gut feelings, faith, and hope” about/of the products, research, and the market I myself have read very very very many Saniona analyses over the last 10-12 years and actually feel it has helped me become a little bit wiser about the case. Not as wise as you and Groland, of course - but wiser nonetheless.
·1 päivä sitten
·1 päivä sittenNext week presentation in USA. Good presentation today, and he didn't know that acadia maybe takes 711 against pain too. And he said maybe jazz does it again meaning agreement. The future looks bright according to me. The analyses made by saniona are alu straight to the trash can. That teso e.g. only needs to move the price a couple of kroner is completely off, but only time will tell if it gets approved. Again, it's peanuts compared to the rest they have. But imagine if it gets approved, there will be talk about saniona steady money in the till. A seal of approval for their products. Acadia on April 21st will talk about 711..
·1 päivä sittenIt's incredible how people perceive the value of Saniona currently, some completely insane price targets and approvals in droves from teso. Some are patted on the back because they are simply super home analysts, even though the share price is going in the exact opposite direction, some promise party hats at 20kr and that didn't go well either. Overall, it's completely irrelevant, but interesting to see how people are shooting in all directions with their own justifications (some only have justifications from others), no one has hit anything that's happening, podium has guessed wrong since 2021-22 and the Swedes have guessed several hundred percent too high. Stig b is back with gloating home analyses which he thinks are correct because he probably sold too early, and with all the shots people are taking, someone must be right sometime, interesting to follow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sitten · MuokattuIf one wants to do some research oneself, here is an interesting document. Together with ChatGPT, I have uploaded Redeye's overview in an Excel sheet and this document, and asked what ChatGPT thinks about it. One can easily buy into 4-5 Phase I projects already now if one wants and put in an F1->F2 LoA now and say it's a fair price - personally I just won't pay for Phase 1 until we are there!l A bit of the ChatGPT dialogue comes here, if one finds it fun - it's a bit of an attempt to take emotions out, so one can always add a bit related to it afterwards: When the individual projects then enter clinical phase - and further to the next phase, one can adjust LoA - the same can be done if new projects, new agreements, new money come in, or if a project is closed. Unfortunately, I cannot upload an Excel sheet, but I think one can quickly make it oneself from Redeye's analysis - that's what I have done myself. ----------------------------------------- Question to ChatGPT: If you were to put some LoA into the attached Excel sheet, what would you put in column M - and would you add something to the calculation. What do you think about the calculation in column O Thought for 6m 19s Yes. I would set column M like this in a 1-factor model: SAN711 Epilepsy: 10% SAN711 Essential Tremor: 18% Tesomet HO/PwS: 25% Tesofensine Obesity: 85% AstronauTx Alzheimer: 2% SAN2355 Epilepsy: 4% SAN2465 Major Depression: 2% Boehringer Schizophrenia: 2% SAN2668 ESES/DEEs: 5% SAN2219 Epilepsy: 3% SAN903: 5% CAD1883: 10% (only if you want to keep the row active) The background is especially that SAN2219 and SAN2465 are still preclinical, SAN2668 first moves towards Phase I in 2026, Tesomet is paused due to funding, Tesofensine is regulatory/NDA-submitted in Mexico, and SAN903 is “ready for clinical studies”. ACP-711/SAN711 has completed Phase I and aims for Phase II in essential tremor. BIO 2011–2020 also supports lower probabilities for CNS than for the average, while rare disease is higher. The most important thing, however, is: I would add an extra factor to the calculation — not mix everything into LoA alone. Add, for example, an auxiliary column with: Execution / funding / partner factor This is especially relevant for: Tesomet (paused) SAN711 epilepsy (more optionality than lead program) discovery/collab-assets like AstronauTx/BI Then the model becomes: Risked value = Unrisked NPV × Technical LoA × Execution factor https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf?utm_source=chatgpt.com
- ·1 päivä sittenShorts are wrong! This is a top-tier company -now on sale.·22 t sitten · MuokattuNice to hear from the man who sits with the crayons, draws some lines in a chart and changes LOA in an analysis until the puzzle fits his own agenda. Of course the price is 'exactly where it should be' then ;)·9 t sitten · MuokattuJUSTICE: That's essentially also what Redeye’s and AktieInfo’s analysts do - so maybe you'd like to share your target price calculations - then one can compare!? They conduct analyses of the products, research, and the market - then they have some assumptions they apply to everything, which they then convert into numbers and a target price - not just sharing “gut feelings, faith, and hope” about/of the products, research, and the market I myself have read very very very many Saniona analyses over the last 10-12 years and actually feel it has helped me become a little bit wiser about the case. Not as wise as you and Groland, of course - but wiser nonetheless.
- ·1 päivä sitten·1 päivä sittenNext week presentation in USA. Good presentation today, and he didn't know that acadia maybe takes 711 against pain too. And he said maybe jazz does it again meaning agreement. The future looks bright according to me. The analyses made by saniona are alu straight to the trash can. That teso e.g. only needs to move the price a couple of kroner is completely off, but only time will tell if it gets approved. Again, it's peanuts compared to the rest they have. But imagine if it gets approved, there will be talk about saniona steady money in the till. A seal of approval for their products. Acadia on April 21st will talk about 711..
- ·1 päivä sittenIt's incredible how people perceive the value of Saniona currently, some completely insane price targets and approvals in droves from teso. Some are patted on the back because they are simply super home analysts, even though the share price is going in the exact opposite direction, some promise party hats at 20kr and that didn't go well either. Overall, it's completely irrelevant, but interesting to see how people are shooting in all directions with their own justifications (some only have justifications from others), no one has hit anything that's happening, podium has guessed wrong since 2021-22 and the Swedes have guessed several hundred percent too high. Stig b is back with gloating home analyses which he thinks are correct because he probably sold too early, and with all the shots people are taking, someone must be right sometime, interesting to follow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 313 | - | - | ||
| 65 | - | - | ||
| 29 | - | - | ||
| 1 037 | - | - | ||
| 57 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 721 971 | 721 971 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 721 971 | 721 971 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
21 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sitten · MuokattuIf one wants to do some research oneself, here is an interesting document. Together with ChatGPT, I have uploaded Redeye's overview in an Excel sheet and this document, and asked what ChatGPT thinks about it. One can easily buy into 4-5 Phase I projects already now if one wants and put in an F1->F2 LoA now and say it's a fair price - personally I just won't pay for Phase 1 until we are there!l A bit of the ChatGPT dialogue comes here, if one finds it fun - it's a bit of an attempt to take emotions out, so one can always add a bit related to it afterwards: When the individual projects then enter clinical phase - and further to the next phase, one can adjust LoA - the same can be done if new projects, new agreements, new money come in, or if a project is closed. Unfortunately, I cannot upload an Excel sheet, but I think one can quickly make it oneself from Redeye's analysis - that's what I have done myself. ----------------------------------------- Question to ChatGPT: If you were to put some LoA into the attached Excel sheet, what would you put in column M - and would you add something to the calculation. What do you think about the calculation in column O Thought for 6m 19s Yes. I would set column M like this in a 1-factor model: SAN711 Epilepsy: 10% SAN711 Essential Tremor: 18% Tesomet HO/PwS: 25% Tesofensine Obesity: 85% AstronauTx Alzheimer: 2% SAN2355 Epilepsy: 4% SAN2465 Major Depression: 2% Boehringer Schizophrenia: 2% SAN2668 ESES/DEEs: 5% SAN2219 Epilepsy: 3% SAN903: 5% CAD1883: 10% (only if you want to keep the row active) The background is especially that SAN2219 and SAN2465 are still preclinical, SAN2668 first moves towards Phase I in 2026, Tesomet is paused due to funding, Tesofensine is regulatory/NDA-submitted in Mexico, and SAN903 is “ready for clinical studies”. ACP-711/SAN711 has completed Phase I and aims for Phase II in essential tremor. BIO 2011–2020 also supports lower probabilities for CNS than for the average, while rare disease is higher. The most important thing, however, is: I would add an extra factor to the calculation — not mix everything into LoA alone. Add, for example, an auxiliary column with: Execution / funding / partner factor This is especially relevant for: Tesomet (paused) SAN711 epilepsy (more optionality than lead program) discovery/collab-assets like AstronauTx/BI Then the model becomes: Risked value = Unrisked NPV × Technical LoA × Execution factor https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf?utm_source=chatgpt.com
- ·1 päivä sittenShorts are wrong! This is a top-tier company -now on sale.·22 t sitten · MuokattuNice to hear from the man who sits with the crayons, draws some lines in a chart and changes LOA in an analysis until the puzzle fits his own agenda. Of course the price is 'exactly where it should be' then ;)·9 t sitten · MuokattuJUSTICE: That's essentially also what Redeye’s and AktieInfo’s analysts do - so maybe you'd like to share your target price calculations - then one can compare!? They conduct analyses of the products, research, and the market - then they have some assumptions they apply to everything, which they then convert into numbers and a target price - not just sharing “gut feelings, faith, and hope” about/of the products, research, and the market I myself have read very very very many Saniona analyses over the last 10-12 years and actually feel it has helped me become a little bit wiser about the case. Not as wise as you and Groland, of course - but wiser nonetheless.
- ·1 päivä sitten·1 päivä sittenNext week presentation in USA. Good presentation today, and he didn't know that acadia maybe takes 711 against pain too. And he said maybe jazz does it again meaning agreement. The future looks bright according to me. The analyses made by saniona are alu straight to the trash can. That teso e.g. only needs to move the price a couple of kroner is completely off, but only time will tell if it gets approved. Again, it's peanuts compared to the rest they have. But imagine if it gets approved, there will be talk about saniona steady money in the till. A seal of approval for their products. Acadia on April 21st will talk about 711..
- ·1 päivä sittenIt's incredible how people perceive the value of Saniona currently, some completely insane price targets and approvals in droves from teso. Some are patted on the back because they are simply super home analysts, even though the share price is going in the exact opposite direction, some promise party hats at 20kr and that didn't go well either. Overall, it's completely irrelevant, but interesting to see how people are shooting in all directions with their own justifications (some only have justifications from others), no one has hit anything that's happening, podium has guessed wrong since 2021-22 and the Swedes have guessed several hundred percent too high. Stig b is back with gloating home analyses which he thinks are correct because he probably sold too early, and with all the shots people are taking, someone must be right sometime, interesting to follow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 313 | - | - | ||
| 65 | - | - | ||
| 29 | - | - | ||
| 1 037 | - | - | ||
| 57 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 721 971 | 721 971 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 721 971 | 721 971 | 0 | 0 |